Aimmune Shares Look Cheap On A Discounted Cash Flow Basis [Seeking Alpha]
DBV Technologies S.A. - American Depositary Shares (DBVT)
US:NASDAQ Investor Relations:
dbv-technologies.com/en/investor-relations
Company Research
Source: Seeking Alpha
SummaryAimmune stock took a beating after the Palforzia approval and COVID-19 pandemic.Despite some current headwinds, Aimmune's long-term trajectory still looks promising, but its stock still trades over 50% below recent highs.My discounted cash flow analysis suggests Aimmune shares are currently undervalued by at least 30%.Aimmune Therapeutics (NASDAQ:AIMTPalforzia Is A Potential Blockbuster That Will Drive Value Growth Over The Next Few YearsThough the timing of the pandemic was certainly poor for Palforzia's launch, the magnitude of the drop in Aimmune's stock is totally out of proportion to the headwinds created by these delayed sales.Figure 1:source:finvizAs you can see from Figure 1, Aimmune has declined over 50% from its recent highs, a drop that is way overdone in my view. Palforzia is a likely blockbuster, and Aimmune currently trades for a little under some of the estimates of Palforzia's peak sales. There is one other therapy for peanut allergy, Viaskin, that is being deve
Show less
Read more
Impact Snapshot
Event Time:
DBVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DBVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DBVT alerts
High impacting DBV Technologies S.A. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
DBVT
News
- DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Egg Allergy Drug Pipeline Research 2024 Featuring Aimmune Therapeutics, DBV Technologies, and ASIT Biotech [Yahoo! Finance]Yahoo! Finance
- DBV Technologies S.A. (NASDAQ: DBVT) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Peanut Allergy Drug Landscape Analysis Report 2024: Comprehensive Insights of 12+ Companies and 15+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2024GlobeNewswire
DBVT
Earnings
- 10/31/23 - Miss
DBVT
Analyst Actions
- 2/21/24 - HC Wainwright
DBVT
Sec Filings
- 4/8/24 - Form PRE
- 3/11/24 - Form 4
- 3/8/24 - Form 8-K
- DBVT's page on the SEC website